

Development of an Optimized Radiopharmaceutical for Targeted Therapy of Metastatic Malignant Melanoma

ONCOLOGY	Candidate
Product Type	RPT
Indication	Melanoma
Target	Malignant melanoma patient
MoA(Mechanism of Action)	① ¹³¹ I-labeled small-molecule binds melanoma ② β- emission cause DNA double-strand breaks with apoptosis/necrosis in melanoma ③ Labeled-molecule enables quantitative imaging for real-time monitoring
Competitiveness	① High tumor-to-organ ratio minimizes normal-tissue exposure ② Melanoma-selective uptake with minimal normal-organ uptake reduces toxicity ③ Faster tumor control and expected survival benefit over standard therapies ④ Rapid clearance enable safe retreatment ⑤ Integrated diagnosis and therapy accelerates translation and cuts selection cost
Development Stage	Candidate
Route of Administration	Intravenous injection

Any unauthorized distribution or reproduction of this material is strictly prohibited.